- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Rossari Biotech Limited's Board has approved the audited financial results for the quarter and financial year ended March 31, 2025. The company reported a total income of ₹20,843.03 crore with a profit after tax of ₹1,363.78 crore, reflecting robust growth driven by increased operational efficiency and higher revenues. Additionally, a final dividend of ₹0.50 per share (25% of face value) has been proposed for approval at the upcoming AGM. The Board appointed M/s. Shah Patel & Associates as Secretarial Auditor for five years and approved the grant of 834,250 options under the Employee Stock Option Plan 2019. The company is also expanding its production capacity by 13,000 MTPA to meet rising market demand, requiring an investment of ₹95 crore, funded through a mix of internal accruals and debt. This expansion signals a positive outlook as it aims to enhance market competitiveness. Investors should note the potential for increased shareholder value from dividends and growth opportunities but remain aware of the risks associated with expanding operations.